Page last updated: 2024-10-18

hydroxymethylbilane and Anemia, Sideroblastic

hydroxymethylbilane has been researched along with Anemia, Sideroblastic in 1 studies

Anemia, Sideroblastic: Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.

Research Excerpts

ExcerptRelevanceReference
"Mutations in the uroporphyrinogen III synthase (UROS) gene cause congenital erythropoietic porphyria (CEP), an autosomal-recessive inborn error of erythroid heme biosynthesis."3.77ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. ( Badenas, C; Beaumont, C; Clayton, J; de Verneuil, H; Delaby, C; Deybach, JC; Ducamp, S; Ferreira, GC; Ged, C; Gouya, L; Herrero, C; Lyoumi, S; Puy, H; To-Figueras, J, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
To-Figueras, J1
Ducamp, S1
Clayton, J1
Badenas, C1
Delaby, C1
Ged, C1
Lyoumi, S1
Gouya, L1
de Verneuil, H1
Beaumont, C1
Ferreira, GC1
Deybach, JC1
Herrero, C1
Puy, H1

Other Studies

1 other study available for hydroxymethylbilane and Anemia, Sideroblastic

ArticleYear
ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
    Blood, 2011, Aug-11, Volume: 118, Issue:6

    Topics: 5-Aminolevulinate Synthetase; Amino Acid Sequence; Anemia, Sideroblastic; Base Sequence; Child, Pres

2011